NR4A1 and breast cancer: Neoadjuvant chemotherapy (NACT) has gained prominence in recent years as an important BC treatment option due to its ability to reduce the cancer burden and promote a pathological complete response (pCR), particularly in BC subtypes that do not express hormone receptors (HRs) [4].